HSD17B13

Across TCGA pan-cancer cohorts, HSD17B13 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated HSD17B13 data layer compared with 20 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher HSD17B13 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HSD17B13 expression acts as an unfavorable survival marker.

ESCA, UCEC, and SCLC are the cancer types where HSD17B13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.212	0.686	.008	18	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SCLC	OS	Median	II,III,IV	0.152	0.777	.038	3	view →
COAD	OS	Median	All	0.464	0.873	.007	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

HSD17B13–ESCA (OS)

Open the ESCA breakdown →